Transfusion-Transmitted Viruses Study (TTVS) - Catalog
-
Name
Transfusion-Transmitted Viruses Study (TTVS)
-
Accession Number
HLB01910909a
-
Acronym
TTVS
-
Related studies(NANB-TAH) Natural History Study of Non-A, Non-B Post-Transfusion Hepatitis (NANB-TAH)
-
BSI Study IDs
TTV
-
Is public use dataset
False
-
Keywords
-
Ingestion Status---------
-
Has Study Datasets
False
-
Has Specimens
True
-
Specimen ID TypeCoded
-
Study Website
-
The Framingham Heart Study Group requires that the requestor must obtain full or expedited IRB/Ethics Committee review and approval to obtain these data. Waivers or a determination that the research is exempt from ethical regulations do not suffice.
False
-
Clinical Trial URLsN/A
-
Study typeEpidemiology Study
-
Collection TypeOpen BioLINCC Study
-
Cohort typeAdult
-
Interventions
-
Study Open Date (Data)
None
-
Study Open Date (Specimens)
2009-10-01
-
Date materials available
2009-09-03
-
Last updated
2023-02-07
-
Study period
1974-1980
-
Study Contacts
-
NHLBI Division
DBDR
-
ClassificationTransfusion Medicine
-
HIV study classificationHIV-Related
-
COVID study classificationnon-COVID
-
Pre-Website # of Specimens Shipped
13146
-
# of Returned Specimens
0
-
Primary Publication URLs
N/A
-
Commercial use data restrictionsNot Applicable (Specimens Only)
-
Data restrictions based on area of researchNot Applicable (Specimens Only)
-
Commercial use specimen restrictionsNo
-
Non-genetic use specimen restrictions based on area of useYes
-
Genetic use of specimens allowed?Yes
-
Genetic use area of research restrictionsYes
-
Specific Consent Restrictions
Consent for both genetic and non-genetic use of biospecimens is restricted to studies involving transfusion safety.
-
ConditionsNANB Hepatitis
-
Objectives
To establish a repository of specimens collected from prospectively identified cases of non-A, non-B (NANB) hepatitis after blood transfusion. The major intentions were to determine the incidence of that occurrence, identify the characteristics of the donors associated with the event, and have a resource available to compare laboratory donor screening methods during the study and in subsequent years following completion of the study.
-
Background
From July 1974 through June 1980, the TTVS group prospectively identified cases of NANB hepatitis in a cohort of 1,533 transfused patients hospitalized short-term for various routine operative procedures. The TTVS collection has been used in a variety of studies, such as the evaluation and validation of Hepatitis C Virus (HCV) immunoassays in screening blood donors (1). In addition, specimens have been requested to evaluate poorly characterized hepatotropic viruses, transmissibility of new viruses (hepatitis G, HHV-8) by transfusion, and the dynamics of HBV/HCV viral replication and seroconversion in recipients.
-
Participants
Serum specimens from 5,655 blood donors were collected from 4 participating blood centers distributed across the US. 3,121 patients were consented to participate in a study of viral hepatitis after blood transfusion. The majority of patients were scheduled for elective surgery. Of these subjects, 1,533 subsequently received blood transfusions. Both transfusion recipients and control subjects that did not require transfusion were observed and blood was collected prior to surgery or pre-transfusion and again during visits at 2-3 week intervals during the first 6 months following the transfusion episode and again between 8-10 months.
A subset of this cohort was subsequently recruited into the Natural History Study of Non-A, Non-B Post Transfusion Hepatitis (NANB-TAH) that also has data and biospecimens available. Subjects cannot be linked between these two studies.
-
Design
The collection originally consisted of aliquots of serum acquired at patient observation visits and from the collection agency for every donor to each TTVS recipient. These sera included the pre-transfusion or pre-surgical specimen, all interval blood draws from these patients and the non-transfused control patients, a specimen from the donor at the time of blood collection and in a subpopulation of donors a follow-up specimen from donors implicated in suspected cases of transfusion transmitted hepatitis and a matched set of non-implicated donors.
-
Conclusions
The TTVS collection provides sera from a large transfusion donor-recipient study in which an untransfused control population with reasonably matched characteristics and of adequate size is available.
-
Disease classification
-
Publications
- Mosley JW, et al. (1990) Non-A, non-B hepatitis and antibody to hepatitis C virus. JAMA 263(1):77-78.
-
Mat typesPlasma or Serum
Serum
-
Network
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request. Section 3.0 of the BioLINCC Handbook describes the components of the review process.
-
Material Types
-
General Freeze/Thaw Status
-
Visits (Vials)
Updated 6th November 2025.
Serum
Plasma or Serum
Total
Recipient Visit 1
9,846
993
10,839
Recipient Visit 2
5,464
21
5,485
Recipient Visit 3
11,395
33
11,428
Recipient Visit 4
10,118
88
10,206
Recipient Visit 5
5,958
296
6,254
Recipient Visit 6
8,136
778
8,914
Recipient Visit 7
4,977
203
5,180
Recipient Visit 8
5,895
289
6,184
Recipient Visit 9
7,955
700
8,655
Recipient Visit 10
5,491
248
5,739
Recipient Visit 11
6,379
309
6,688
Recipient Visit 12
6,657
595
7,252
Recipient Visit 13
3,547
170
3,717
Recipient Visit 14
1,757
51
1,808
Recipient Visit 15
1,047
28
1,075
Recipient Visit 16
758
20
778
Recipient Visit 17
673
13
686
Recipient Visit 18
549
14
563
Recipient Visit 19
507
8
515
Recipient Visit 20
405
7
412
Recipient Visit 21
327
3
330
Recipient Visit 22
247
5
252
Recipient Visit 23
193
0
193
Recipient Visit 24
198
2
200
Recipient Visit 25
155
1
156
Recipient Visit 26
95
0
95
Recipient Visit 27
83
0
83
Recipient Visit 28
79
0
79
Recipient Visit 29
80
0
80
Recipient Visit 30
59
0
59
Recipient Visit 31
60
0
60
Recipient Visit 32
42
0
42
Recipient Visit 33
30
0
30
Recipient Visit 34
30
0
30
Recipient Visit 35
28
0
28
Recipient Visit 36
23
0
23
Recipient Visit 37
21
0
21
Recipient Visit 38
12
0
12
Recipient Visit 39
26
0
26
Recipient Visit 40
21
0
21
Recipient Visit 41
13
0
13
Recipient Visit 42
14
0
14
Recipient Visit 43
18
0
18
Donor 1
11,350
1,302
12,652
Donor 2
9,504
1,036
10,540
Donor 3
6,108
599
6,707
Donor 4
4,684
423
5,107
Donor 5
3,294
297
3,591
Donor 6
2,410
217
2,627
Donor 7
1,613
147
1,760
Donor 8
1,077
107
1,184
Donor 9
711
68
779
Donor 10
450
35
485
Donor 11
323
33
356
Donor 12
207
20
227
Donor 13
115
11
126
Donor 14
69
4
73
Donor 15
14
3
17
Donor 17
1
0
1
Last Modified: Nov. 6, 2025, 1:53 p.m. -
Visits (Subjects)
Updated 6th November 2025.
Serum
Total number of subjects
Average volume (ml) per subject
Recipient Visit 1
1,492
3.22
Recipient Visit 2
1,263
4.22
Recipient Visit 3
1,499
3.54
Recipient Visit 4
1,444
3.70
Recipient Visit 5
1,285
4.02
Recipient Visit 6
1,404
3.76
Recipient Visit 7
1,234
4.21
Recipient Visit 8
1,295
4.13
Recipient Visit 9
1,401
3.74
Recipient Visit 10
1,232
4.21
Recipient Visit 11
1,253
3.97
Recipient Visit 12
1,202
3.69
Recipient Visit 13
853
4.07
Recipient Visit 14
370
3.88
Recipient Visit 15
199
3.64
Recipient Visit 16
141
3.67
Recipient Visit 17
114
3.53
Recipient Visit 18
96
3.45
Recipient Visit 19
84
3.69
Recipient Visit 20
69
3.79
Recipient Visit 21
61
3.56
Recipient Visit 22
42
3.50
Recipient Visit 23
38
3.40
Recipient Visit 24
35
3.44
Recipient Visit 25
27
3.22
Recipient Visit 26
22
2.39
Recipient Visit 27
20
3.06
Recipient Visit 28
15
2.91
Recipient Visit 29
14
2.68
Recipient Visit 30
13
2.68
Recipient Visit 31
12
2.71
Recipient Visit 32
8
2.63
Recipient Visit 33
6
2.71
Recipient Visit 34
5
2.84
Recipient Visit 35
4
2.86
Recipient Visit 36
3
3.37
Recipient Visit 37
3
3.18
Recipient Visit 38
3
2.50
Recipient Visit 39
3
2.12
Recipient Visit 40
3
2.50
Recipient Visit 41
2
3.88
Recipient Visit 42
3
1.92
Recipient Visit 43
2
3.38
Donor 1
1,512
4.31
Donor 2
1,246
4.40
Donor 3
816
4.14
Donor 4
606
4.23
Donor 5
446
4.12
Donor 6
327
4.01
Donor 7
227
3.99
Donor 8
152
3.94
Donor 9
104
3.87
Donor 10
68
3.93
Donor 11
49
3.99
Donor 12
30
4.04
Donor 13
16
3.89
Donor 14
10
3.51
Donor 15
3
4.17
Donor 17
1
2.50
Plasma or Serum
Total number of subjects
Average volume (ml) per subject
Recipient Visit 1
985
0.22
Recipient Visit 2
21
0.25
Recipient Visit 3
32
0.26
Recipient Visit 4
85
0.24
Recipient Visit 5
293
0.25
Recipient Visit 6
773
0.26
Recipient Visit 7
203
0.25
Recipient Visit 8
289
0.25
Recipient Visit 9
696
0.26
Recipient Visit 10
247
0.24
Recipient Visit 11
305
0.24
Recipient Visit 12
591
0.24
Recipient Visit 13
165
0.23
Recipient Visit 14
49
0.24
Recipient Visit 15
27
0.22
Recipient Visit 16
19
0.21
Recipient Visit 17
13
0.21
Recipient Visit 18
14
0.19
Recipient Visit 19
8
0.18
Recipient Visit 20
7
0.19
Recipient Visit 21
3
0.20
Recipient Visit 22
5
0.17
Recipient Visit 24
2
0.15
Recipient Visit 25
1
0.05
Donor 1
939
0.23
Donor 2
770
0.23
Donor 3
474
0.23
Donor 4
334
0.23
Donor 5
253
0.22
Donor 6
180
0.23
Donor 7
126
0.23
Donor 8
90
0.21
Donor 9
58
0.21
Donor 10
32
0.20
Donor 11
31
0.21
Donor 12
18
0.22
Donor 13
11
0.20
Donor 14
4
0.24
Donor 15
3
0.23
Last Modified: Nov. 6, 2025, 1:53 p.m.